

## **Product datasheet for TP721380M**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **CLDN6 Human Recombinant Protein, Membrane Nanoparticle**

**Product data:** 

**Product Type:** Recombinant Proteins

Description: Recombinant Human CLDN6 full length protein -Membrane Nanoparticle, 100µg

Species: Human Expression Host: HEK293

**Expression cDNA Clone** 

or AA Sequence:

C-terminal Flag tagged overexpression cDNA clone

Tag: C-term Flag Tag

Predicted MW: The human full length CLDN6 Protein has a MW of 23 kDa

**Concentration:** Please refer to the Certificate of Analysis (COA) for the lot-specific concentration before

lyophilization.

**Buffer:** Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants

before lyophilization.

Reconstitution Method:1. Before opening the tube cap, centrifuge the sample tube at 5000g for 3-5min at room

temperature to ensure the lyophilized sample settles down at the bottom of the tube.

2. Calculate the volume for reconstitution (in µL) using the formula: [Quantity

(mg)/Concentration (mg/mL)]x1000

3. Dissolve the lyophilized protein sample in sterile water based on the calculated volume (µL)

4. After adding sterile water, cover the lid and mix by gently tapping the tube 5-10 times. Note:

Do not vortex or vigorously pipette the sample.

Storage: Store at -20°C to -80°C for 12 months in lyophilized form.

**Stability:** After reconstitution, if not intended for use within a month, aliquot and store at -80°C. Avoid

repeated freezing and thawing.

**Locus ID:** 9074

UniProt ID: P56747

Synonyms: Claudin 6; Claudin-6; Skullin; Claudin6

Protein Families: GPCR

**Protein Pathways:** Neuroactive ligand-receptor interaction





## **Product images:**




Figure 2. FACS analysis of CLDN6 MNPs A. Negative Control 1: CLDN6 full length membrane nanoparticles samples were stained only with Goat anti-human IgG 488 secondary antibody. B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-CLDN6 antibody at 2µg/mL, followed by Goat anti-human IgG 488 secondary antibody. C. Negative Control 3: CLDN6 full length membrane nanoparticles samples were stained with anti-GPRC5D antibody (an irrelevant antibody) at 2µg/mL, followed by Goat anti-human IgG 488 secondary antibody. D. CLDN6 full length membrane nanoparticles samples were stained with anti-CLDN6 antibody at 2µg/mL, followed by Goat anti-human IgG 488 secondary antibody.

ELISA assay to evaluate CLDN6-MNPs 0.5µg Human CLDN6-MNPs per well




Figure 1. Elisa plates were pre-coated with 0.5µg/per well purified human CLDN6 full length membrane nanoparticles. Serial diluted anti-CLDN6 monoclonal antibody solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CLDN6 monoclonal antibody binding with CLDN6 full length membrane nanoparticles is 34.36ng/ml.